Lisa Bodei
European Institute of Oncology
Internal medicineRadiologyEndocrinologyPathologyOncologyReceptorRadioimmunotherapySomatostatinNeuroendocrine tumorsOctreotideToxicityNuclear medicineRadionuclide therapyPeptide receptorCancer researchRadiation therapyMedicineBiomarker (medicine)Chromogranin ASomatostatin receptorGastroenterology
117Publications
50H-index
5,844Citations
Publications 115
Newest
#1Anna MalczewskaH-Index: 12
#2Beata Kos-KudłaH-Index: 31
Last. Lisa BodeiH-Index: 50
view all 8 authors...
1 CitationsSource
#1Irvin M. ModlinH-Index: 81
#2Mark KiddH-Index: 66
Last. Kyung-Min ChungH-Index: 5
view all 7 authors...
Source
#1Irvin M. ModlinH-Index: 81
#2Mark KiddH-Index: 66
Last. Ignat DrozdovH-Index: 37
view all 18 authors...
Source
#1Irvin M. ModlinH-Index: 81
#2Mark KiddH-Index: 66
Last. Kyung-Min ChungH-Index: 5
view all 7 authors...
Source
#1Rodney J. HicksH-Index: 90
#2Dik J. KwekkeboomH-Index: 74
Last. John RamageH-Index: 41
view all 14 authors...
The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in de
110 CitationsSource
#1Anna SarnelliH-Index: 14
#2Francesco Guerriero (IEO: European Institute of Oncology)H-Index: 6
Last. Marta Cremonesi (IEO: European Institute of Oncology)H-Index: 42
view all 12 authors...
The purpose of this work is to implement a radiobiological model to compare different treatment schedules for Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu and 90Y. The principal radiobiological quantities were studied as a function of radionuclides, fractionation schemes, activity distribution in kidneys and tumor radiosensitivity.Clinical data were used to derive representative absorbed doses for several treatment schemes for 177Lu-PRRT and for 90Y-PRRT and considered as input data f...
9 CitationsSource
#1Diane Lauren Reidy (Cornell University)H-Index: 20
#2Neeta Pandit-Taskar (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 42
Last. Wolfgang A. Weber (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 67
view all 10 authors...
4094Background: Radiolabeled somatostatin receptor 2 (sstr2) antagonists have shown higher tumor uptake and tumor-to-organ ratios than agonists in preclinical models. We performed a phase I study to evaluate the safety and radiation dosimetry of the sstr2 antagonists 68Ga-OPS202 and 177Lu-OPS201 (68Ga/177Lu-DOTA-JR11) in patients (pts) with metastatic well differentiated NETs (NCT02609737). Efficacy data after 177Lu-OPS201were recorded. Methods: Pts with RECIST disease progression underwent a 68...
7 CitationsSource
Purpose Lu-DOTATATE (Lu-PRRT) is a valid therapeutic option in differentiated pancreatic neuroendocrine tumors (P-NETs). FDG PET seems to be an important prognostic factor in P-NETs. We evaluated the efficacy of Lu-PRRT and the role of FDG PET in 60 patients with advanced P-NETs.
60 CitationsSource
#1Lisa Bodei (IEO: European Institute of Oncology)H-Index: 50
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 10 authors...
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Background: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for neuroendocrine tumors (NETs). Somatostatin receptor expression defines suitability for therapy. Elevated somatostatin receptor uptake (Krenning scale grade 4) at baseline has ∼60% predictive accuracy for efficacy. Increased (>600ng/ml) baseline levels of chromogranin A (CgA) are also considered as predictive. A blood-based 51 multi...
Source
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Lisa Bodei (IEO: European Institute of Oncology)H-Index: 50
view all 5 authors...
Background: A key issue in the clinical management of gastroenteropancreatic neuroendocrine tumors (GEP-NET) is early identification and the prediction of disease progression or recurrence. Strategies include imaging and biomarker measurement e.g., CgA or NSE. The former is limited by sensitivity and the latter by low specificity and poor reproducibility. We evaluated the role of a blood-based multianalyte gene algorithmic analysis (MAAA) using a 51 NET gene signature (NETest) as an alternative ...
Source